Ticker: NEO

NeoGenomics

Healthcare Healthcare Medical - Diagnostics & Research
Price 14.82
Reco Sell Potential 43 Risk 70 Updated 2026-11-19

Forecast impact

neutral
Target +52.4% target fill 65.6%
Reaction D5 -4.18% · D10 -1.65%
Impact Potential 0 · Risk 0 valid until 2026-11-28

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

NeoGenomics is a healthcare company specializing in cancer diagnostics and genomic testing services. Its core products include a range of molecular and genomic tests that assist in cancer diagnosis, treatment selection, and monitoring. Major business segments encompass clinical testing services and pharmaceutical services, with primary revenue sources derived from laboratory testing and partnerships with pharmaceutical companies for clinical trials.

Investment Profile

The investment profile of NeoGenomics suggests it may be more suitable for value investors, given its current pricing relative to earnings and growth potential. The stock exhibits characteristics that may appeal to those seeking a balanced approach, though it carries higher risk factors. Investors should consider the company's volatility and market position when evaluating their investment horizon.

Fundamental metrics (experimental) Updated: 2026-11-20
EPS (TTM) — earnings per share for the last 12 months, $
-0.25
Revenue QoQ — quarter-over-quarter revenue growth
3.8%
EPS surprise
26.2%
20d volatility
2.6%
last ex-date
2020-12-17
AI recommendation changes
Date Before After Reason
2026-11-14 Hold Sell Weak fundamentals and negative momentum raise significant concerns.
2026-10-31 Sell Hold Weak fundamentals with mixed momentum signals.
2026-10-23 Hold Sell Weak fundamentals and negative momentum raise significant concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-10-29 TD Cowen Target Raised 19 → 23 17.93
2026-10-29 Jefferies Target Raised 16.5 → 21 17.0304
2026-10-06 Needham Target Raised — → 22 19.13
News Page 1 of 1